These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 1741398)
1. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Gillies SD; Reilly EB; Lo KM; Reisfeld RA Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1428-32. PubMed ID: 1741398 [TBL] [Abstract][Full Text] [Related]
2. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Naramura M; Gillies SD; Mendelsohn J; Reisfeld RA; Mueller BM Immunol Lett; 1993 Dec; 39(1):91-9. PubMed ID: 8144194 [TBL] [Abstract][Full Text] [Related]
4. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070 [TBL] [Abstract][Full Text] [Related]
5. GD3-reactive antibodies can inhibit the lysis of autologous tumor cells by tumor-infiltrating lymphocytes. Reilly EB; Antognetti G Cancer Immunol Immunother; 1992; 35(1):59-62. PubMed ID: 1611624 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of cytotoxic and proliferative responses of lymphocytes from melanoma patients by incubation with monoclonal antibodies against ganglioside GD3. Hersey P; MacDonald M; Burns C; Cheresh DA Cancer Immunol Immunother; 1987; 24(2):144-50. PubMed ID: 3493846 [TBL] [Abstract][Full Text] [Related]
7. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Itoh K; Tilden AB; Balch CM Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040 [TBL] [Abstract][Full Text] [Related]
8. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Sabzevari H; Gillies SD; Mueller BM; Pancook JD; Reisfeld RA Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9626-30. PubMed ID: 7937818 [TBL] [Abstract][Full Text] [Related]
9. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817 [TBL] [Abstract][Full Text] [Related]
11. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139 [TBL] [Abstract][Full Text] [Related]
12. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620 [TBL] [Abstract][Full Text] [Related]
15. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Lo AS; Ma Q; Liu DL; Junghans RP Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472 [TBL] [Abstract][Full Text] [Related]
16. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004 [TBL] [Abstract][Full Text] [Related]
17. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095 [TBL] [Abstract][Full Text] [Related]
18. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Becker JC; Pancook JD; Gillies SD; Mendelsohn J; Reisfeld RA Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2702-7. PubMed ID: 8610104 [TBL] [Abstract][Full Text] [Related]
19. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368 [TBL] [Abstract][Full Text] [Related]
20. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]